🇯🇵·14h agoIndustry
Otsuka Presents Positive Interim Phase 3 VISIONARY eGFR Data Showing VOYXACT (sibeprenlimab-szsi) Preserved Kidney Function Over 12 Months in IgA Nephropathy (IgAN)
Publisher
O
Otsuka Holdings RSS
Japan
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on otsuka.co.jp
Leave the platform to read the original full article on the publisher site.
Source: Otsuka Holdings RSS
Scope: Industry
Related coverage
More related coverage
Nippon Shinyaku News·5h ago
「第163期 定時株主総会招集ご通知」の一部訂正についてを掲載しました
Farmak (Ukraine)·6h ago
How “Non-Stop” and “Antikor” Have Spent Years Fabricating False Claims About Farmak
Otsuka Pharmaceutical·7h ago
Otsuka Establishes "Heatstroke Countermeasure Industry-Government-Academia Consortium" with the National Institute for Environmental Studies and Other Partners
Ipsen·8h ago